Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workersOriginal Paper Published on 2021-09-032022-10-29 Journal: Journal of Medical Biochemistry [Category] COVID-19, [키워드] access administration age anti-SARS-CoV-2 Anti-spike Anti-spike RBD IgG antibodies antibody antitela association baseline Beckman Coulter BNT162b2 Cell-mediated immunity collected coronavirus disease COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccination COVID-19 vaccine DiaSorin dose elicit elicited ELISA healthcare healthcare worker IgA IgA antibody IgG immune response imuni odgovor interquartile range IQR median median age MOST mRNA Neutralizing neutralizing antibody occurred Pfizer RBD receiving Receptor binding domain remained Result S1 subunit SARS-CoV-2 SARSCoV-2 seronegative serum IgG serum IgG antibody Serum level serum sample Significant significantly study population subject sustained trimeric vaccination vaccine dose vakcinacija viral infection women [DOI] 10.5937/jomb0-32373 PMC 바로가기 [Article Type] Original Paper
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infectionSARS-CoV-2 감염 후 14개월 동안 항체 반응에 대한 종단 관찰Observational Study Published on 2021-09-012022-09-11 Journal: Clinical immunology (Orlando, Fla.) [Category] SARS, 임상, 진단, 치료법, [키워드] Analysis analyzed anti-S Anti-spike Antibody assays Antibody Response Antibody responses Antibody titer Antibody titers Better binding domain carried Clinical course clinical history coronavirus COVID19 demographics different time points false-negative rate highlight Humoral immunity IgG IgG antibody IgG antibody titer IgG antibody titers immunoassay immunoassays implementation Italy Longevity longitudinal longitudinal analysis Loss of Smell loss of smell and taste magnitude natural infection Neutralizing antibodies observation positive Protein RBD IgG Re-infection Re-infections recovered COVID-19 patient recovered patients S-RBD SARS-CoV-2 SARS-COV-2 infection serological test Serological tests seronegative significantly higher subject Symptom Taste tested the disease vaccination were used [DOI] 10.1016/j.clim.2021.108814 PMC 바로가기 [Article Type] Observational Study
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)SARS-CoV-2 mRNA 백신(BNT162b2) 2회 접종 후 의료 전문가의 조기 항체 반응Multicenter Study Published on 2021-09-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, 진단, 치료법, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-spike antibodies anti-spike antibody antibody Antibody Response Antibody titre antibody titres baseline Belgium blood sample Blood samples BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine clinical trial collected conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine disease dose dose regimen hcp health-care Humoral response immune response individual individuals infected individual infected individuals lead mRNA vaccine multicentre nucleocapsid of BNT162b2 optimum dose professional reached Receptor binding domain respiratory S1 subunit SARS-CoV-2 SARS-CoV-2 nucleocapsid second dose seronegative severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly higher single dose Spike protein Support the S1 subunit the SARS-CoV-2 the spike protein titre two-dose regimen uninfected Vaccine Volunteer were excluded were measured [DOI] 10.1016/j.cmi.2021.05.004 PMC 바로가기 [Article Type] Multicenter Study
Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report리툭시맙에 대한 SARS-CoV-2 혈청 음성 환자의 COVID-19 예방 접종 반응을 평가하기 위한 인터페론-감마 방출 분석 테스트: 증례 보고Case Reports Published on 2021-09-012022-09-12 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome Case report cell-mediated response coronavirus COVID-19 vaccination female humoral IgG Impaired Impaired humoral immunity Interferon-gamma lack multiple sclerosis Patient positive robust SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose seronegative specific antibody T cell T cell respone. Treatment undetectable [DOI] 10.1016/j.ijid.2021.06.054 PMC 바로가기 [Article Type] Case Reports
Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies가벼운 SARS-CoV-2 질병은 재감염과 관련이 없으며 지속적인 스파이크, 뉴클레오캡시드 및 바이러스 중화 항체를 제공합니다Research Article Published on 2021-09-012022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 진단, 치료법, [키워드] antibodies antibody antibody assay Antibody assays Antibody Response assays clinical conducted correlated COVID-19 COVID-19 antibody COVID-19 infection COVID-19 testing decrease disease Enrollment Evidence evidence of exposure to FDA Follow-up Hospitalization illness Immunity immunoassay immunoassays immunoserology individual Infection infection rates Mild Mild disease mild infection MOST neutralization activity nucleocapsid nucleocapsid responses Participants persistence persistent produced prospective cohort study pseudoviral neutralization Reinfection risk RT-PCR RT-PCR assays SARS-CoV-2 SARS-CoV-2 RT-PCR screened Seroconversion serology seronegative seropositive subject spike study duration subject subsequent Symptoms Uncertainty vaccination Vaccine Viral viral neutralization widespread [DOI] 10.1128/Spectrum.00087-21 PMC 바로가기 [Article Type] Research Article
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients만성 투석 환자에서 SARS-CoV-2에 대한 메신저 RNA 기반 백신의 높은 면역원성Article Published on 2021-08-272022-09-12 Journal: Nephrology, dialysis, transplantation : official p [Category] MERS, 진단, [키워드] acute respiratory syndrome Administered anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies antibody Chronic kidney disease coronavirus COVID-19 COVID-19 vaccine dialysis dose doses Follow-up Haemodialysis high risk Immunosuppression immunosuppressive independent injection intramuscularly kidney kidney transplant Messenger RNA mRNA mRNA vaccine mRNA vaccines nine non-responder of BNT162b2 offered Patient patients Peritoneal dialysis Pfizer-BioNTech Predictive required SARS-CoV-2 second dose seroconversion rate seronegative seronegative patient severe coronavirus disease tested the vaccine therapy vaccination Vaccine vaccine dose were given [DOI] 10.1093/ndt/gfab193 PMC 바로가기 [Article Type] Article
Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic DrugsArticle Published on 2021-08-202022-10-31 Journal: Cancers [Category] COVID-19, [키워드] adjusted age age and gender analyzed anti-cancer treatment antibody Antibody Response anticancer Assessing BNT162b2 BNT162b2 vaccine Cancer cancer patient Cancer patients Chemotherapy Chemotherapy treatment chronic disease COVID-19 COVID-19 vaccine diagnosed drug drugs Effect effective Efficacy facial Gender humoral IgG IgG level immunization Immunotherapy in healthy individual individuals Infection IQR malignant disease manifested measure median Multivariate analysis negative serological response Odds ratio of BNT162b2 participant Patient patients patients treated Protective raise receiving reduced reducing risk risk of COVID-19 SARS-CoV-2 SARS-COV-2 infection second dose Serologic response serological response serology seronegative shown significantly lower significantly more simple social distancing Solid solid malignancy therapy those without cancer treated Treatment two group vaccination was performed worldwide pandemic [DOI] 10.3390/cancers13164191 PMC 바로가기 [Article Type] Article
Picture of the Favourable Immune Profile Induced by Anti-SARS-CoV-2 VaccinationArticle Published on 2021-08-182022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] administration analysed anti-S1 IgG anti-SARS-CoV-2 IgG antibody Antigen-specific T cells AZD1222 Blood BNT162b2 carried Cohort COVID-19 pandemic doses Efficacy evaluated first dose Health IgG level Immune profile immunological protection independent individual induce induced knowledge normality of BNT162b2 produced profile random required SARS-CoV-2 SARS-COV-2 infection seronegative severe adverse effect spike-specific T-cells subject subjects T-cell T-cells vaccination Vaccination strategy Vaccine Vaccines [DOI] 10.3390/biomedicines9081035 PMC 바로가기 [Article Type] Article
Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 PandemicCOVID-19 팬데믹의 첫 두 물결 동안 캐나다 앨버타주에서 SARS-CoV-2 항체의 백신 사전 양성Research Article Published on 2021-08-182022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 진단, 치료기술, 치료법, [키워드] 95% CI 95% confidence interval antibodies antibody best blood sample Canada clinical laboratories Cohort collected Concordance correlated correlation COVID-19 COVID-19 pandemic demographics detectable Epidemiology evaluated facilitate female followed by geographical areas group help highest highlight immunology in some individual Infection information Laboratory Local lowest male minority groups molecular molecular test NAAT no significant difference nucleic acid test nucleocapsid protein Patient population prevalence positive positive COVID-19 proportion provide public health residual SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 nucleocapsid SARS-CoV-2 virus second wave secondary school seeking serology serology testing seronegative seropositive seropositive individual seropositive individuals Seropositivity Seroprevalence Sociodemographic Spike protein Support tested the SARS-CoV-2 virus vaccination Wave [DOI] 10.1128/Spectrum.00291-21 PMC 바로가기 [Article Type] Research Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial남아프리카에 HIV가 있거나없는 사람들의 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 무작위, 이중 맹검, 위약 대조, Phase 1B/2A 시험의 중간 분석Clinical Trial Published on 2021-08-172022-08-13 Journal: The Lancet. HIV [Category] MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 1B/2A trial 95% CI adverse event adverse events African Alanine alanine aminotranferase allocation concealment Antibody Response Antibody Units Antiretroviral therapy Asp614Gly wild-type AZD1222 B.1.351 baseline Beta Beta variant binding antibodies binding antibody unit booster booster response both groups ChAdOx1 ChAdOx1 nCov 19 ChAdOx1 nCoV-19 clinical COV005 criteria cross-reactive binding antibodies cross-reactive binding antibody cross-reactivity D614G demonstrated died domain dose double-blind elevated eligibility criteria enrolled enrolment Fever finding FIVE foundation full-length funding geometric mean geometric mean concentration GMC high responder high responders High-level binding antibody HIV HIV-negative hospital IgG responses immunogenicity in both groups increased risk individual individuals Innovation interim analysis Intervention less Medical Research Council Melinda Gate Melinda Gates n=36 nCoV neutralisation Neutralising activity outcome Pan participant Participants people with HIV person with HIV Placebo placebo-controlled plasma Primary immunogenicity analyses Primary immunogenicity analysis prime-boost regimen priming priming dose randomised Randomly reactogenicity receive Receptor-binding domain Registered registry responses responses against retained rising Safety SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens Serious Adverse Events seronegative seropositive serum IgG Seven severe COVID-19 South South Africa titre Trial unlikely Vaccine vaccine dose Viral Viral load wild-type wild-type Wuhan-1 Asp614Gly with HIV [DOI] 10.1016/S2352-3018(21)00157-0 PMC 바로가기 [Article Type] Clinical Trial